PubRank

Natalie A Sims

Author PubWeight™ 69.46‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 2007 3.82
2 Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 2010 3.26
3 Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005 2.72
4 Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 2009 2.09
5 EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res 2008 1.97
6 Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. Blood 2011 1.96
7 SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J Clin Invest 2006 1.92
8 Defective microtubule-dependent podosome organization in osteoclasts leads to increased bone density in Pyk2(-/-) mice. J Cell Biol 2007 1.92
9 Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol 2004 1.88
10 The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A 2009 1.63
11 EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone. J Bone Miner Res 2013 1.55
12 The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005 1.45
13 Model structure and control of bone remodeling: a theoretical study. Bone 2008 1.44
14 Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 2006 1.42
15 Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002 1.38
16 A novel mutation in the Nfkb2 gene generates an NF-kappa B2 "super repressor". J Immunol 2007 1.34
17 Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr 2009 1.34
18 Elevated hypothalamic TCPTP in obesity contributes to cellular leptin resistance. Cell Metab 2011 1.21
19 Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Invest 2010 1.18
20 Generation and analysis of Siah2 mutant mice. Mol Cell Biol 2003 1.15
21 Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res 2006 1.11
22 Arthritogenic alphaviral infection perturbs osteoblast function and triggers pathologic bone loss. Proc Natl Acad Sci U S A 2014 1.10
23 What is the true nature of the osteoblastic hematopoietic stem cell niche? Trends Endocrinol Metab 2009 1.09
24 Gsα enhances commitment of mesenchymal progenitors to the osteoblast lineage but restrains osteoblast differentiation in mice. J Clin Invest 2011 1.08
25 EphB/ephrin-B interactions mediate human MSC attachment, migration and osteochondral differentiation. Bone 2010 1.08
26 Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res 2008 1.08
27 Zinc finger protein 467 is a novel regulator of osteoblast and adipocyte commitment. J Biol Chem 2010 1.02
28 The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J Bone Miner Res 2010 1.02
29 Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function. FASEB J 2009 0.99
30 IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. J Immunol 2008 0.99
31 Tissue inhibitor of metalloproteinase-3 (TIMP-3) regulates hematopoiesis and bone formation in vivo. PLoS One 2010 0.99
32 Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. J Theor Biol 2009 0.98
33 Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin Cancer Res 2009 0.93
34 An ethyl-nitrosourea-induced point mutation in phex causes exon skipping, x-linked hypophosphatemia, and rickets. Am J Pathol 2002 0.91
35 Gp130-mediated signaling is necessary for normal osteoblastic function in vivo and in vitro. Endocrinology 2003 0.91
36 Matrix metalloproteinases are not essential for aggrecan turnover during normal skeletal growth and development. Mol Cell Biol 2005 0.91
37 The chemokine Cxcl1 is a novel target gene of parathyroid hormone (PTH)/PTH-related protein in committed osteoblasts. Endocrinology 2009 0.90
38 Contrasting roles of leukemia inhibitory factor in murine bone development and remodeling involve region-specific changes in vascularization. J Bone Miner Res 2012 0.89
39 Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro. Bone 2006 0.88
40 Lack of sustained response to teriparatide in a patient with adult hypophosphatasia. J Clin Endocrinol Metab 2010 0.86
41 RANKL/OPG; Critical role in bone physiology. Rev Endocr Metab Disord 2015 0.86
42 Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo. J Bone Miner Res 2012 0.86
43 Vaginally administered PEGylated LIF antagonist blocked embryo implantation and eliminated non-target effects on bone in mice. PLoS One 2011 0.85
44 The primary function of gp130 signaling in osteoblasts is to maintain bone formation and strength, rather than promote osteoclast formation. J Bone Miner Res 2014 0.84
45 Adverse effects of valproate on bone: defining a model to investigate the pathophysiology. Epilepsia 2010 0.84
46 Ciliary neurotrophic factor inhibits bone formation and plays a sex-specific role in bone growth and remodeling. Calcif Tissue Int 2010 0.83
47 Skeletal recovery after weaning does not require PTHrP. J Bone Miner Res 2011 0.83
48 Strain-dependent differences in bone development, myeloid hyperplasia, morbidity and mortality in ptpn2-deficient mice. PLoS One 2012 0.83
49 EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair. J Bone Miner Res 2013 0.82
50 Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects. J Clin Endocrinol Metab 2012 0.82
51 Osteopenia in Siah1a mutant mice. J Biol Chem 2004 0.82
52 Delayed development of specific thyroid hormone-regulated events in transthyretin null mice. Am J Physiol Endocrinol Metab 2012 0.82
53 Decline in calcitonin receptor expression in osteocytes with age. J Endocrinol 2014 0.79
54 Lactating Ctcgrp nulls lose twice the normal bone mineral content due to fewer osteoblasts and more osteoclasts, whereas bone mass is fully restored after weaning in association with up-regulation of Wnt signaling and other novel genes. Endocrinology 2013 0.79
55 Osteoclast inhibitory lectin, an immune cell product that is required for normal bone physiology in vivo. J Biol Chem 2008 0.79
56 Talking among ourselves: paracrine control of bone formation within the osteoblast lineage. Calcif Tissue Int 2013 0.78
57 Calcitonin physiology, saved by a lysophospholipid. J Bone Miner Res 2015 0.77
58 Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis? Blood 2008 0.76
59 Correction: Chondrocytic ephrin B2 promotes cartilage destruction by osteoclasts in endochondral ossification. Development 2017 0.75
60 Intermittent Fugu parathyroid hormone 1 (1-34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats. Bone 2008 0.75